Abstract: A method for administering ECyd to a patient that realizes a continuous therapy without expressing peripheral neurotoxicity caused by ECyd and that exhibits an excellent therapeutic effect and prolongs patient survival. An antitumor agent containing ECyd or a salt thereof and a method of administering it to a cancer patient through continuous intravenous administration at a dose of 1.30 to 8.56 mg/m2 in terms of ECyd, for each administration period of 2 to 336 hours.

Abstract: To provide a method for administering ECyd to a patient, which realizes a continuous therapy without expressing peripheral neurotoxicity caused by ECyd and which exhibits an excellent therapeutic effect with ensuring prolongation of the survival of the patient. The invention provides an antitumor agent containing ECyd or a salt thereof, which is administered to a cancer patient through continuous intravenous administration at a dose of 1.30 to 8.56 mg/m2 as reduced to ECyd, for each administration period of 2 to 336 hours.

Abstract: An antitumor effect fortifier comprising as an active ingredient an effective amount of platinum (II) cis-oxalato(1R,2R-diaminocyclohexane) so as to enhance the antitumor activity of antitumor agent containing a therapeutically effective amount of tegafur, an amount, effective for the enhancement of antitumor effect, of gimeracil and an amount, effective for the suppression of side effects, of oteracil potassium; and a relevant antitumor agent. Further, there is provided a method of therapy for cancer, characterized in that an amount, effective for the enhancement of antitumor effect, of platinum (II) cis-oxalato(1R,2R-diaminocyclohexane) is concomitantly administered to a mammal.

Abstract: A DNA array for measuring sensitivity to an antimetabolite-type anticancer agent or a combined use of such an anticancer agent and another anticancer agent, characterized by including at least 13 types of target gene fragments, involving at least two types of genes selected from each of the following groups: nucleic acid metabolism-associated enzyme genes, gene repair-associated enzyme genes, drug resistance-associated factor genes and housekeeping genes, wherein these gene fragments have been selected by the following steps 1) and 2) and immobilized on a substrate; 1) a step of selecting fragments having high specificity for target genes by searching the homology with the use of databases; and 2) a step of performing Northern hybridization against RNA obtained from tumor cells with the use of the fragments selected in the step 1) as probes to thereby confirm the specificity for the target genes.